1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Invion Limited

Invion Limited

IVX.AX
Invion LimitedAU flagAustralian Securities Exchange
0.03
AUD
- -
- -
3.49MMarket Cap
Invion Limited
IVX.AX
(Australian Securities Exchange)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.07
0.06
0.04
0.05
0.06
0.06
- -
Revenue per Share
-19.12
-8.69
-2.04
-1.12
-1.11
-1.7
-0.33
-0.14
-0.13
-0.02
-0.02
-0.03
-0.04
-0.03
-0.09
-0.12
Basic EPS, GAAP
-0.01
-0.03
-0.06
- -
-0.05
-0.03
- -
- -
- -
- -
- -
- -
-0.12
-0.04
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-27.19
-13.69
-5.19
-1.98
-1.7
-2.16
-1.31
-1.22
-0.42
-0.32
0.06
0.04
0.26
0.26
0.19
0.09
Book Value per Share
16.31
10.97
2.22
-0.06
0.05
-0.63
-0.35
-0.05
0.02
0.01
0.01
- -
0.13
0.08
0.02
- -
Tangible Book Value per Share
1
2
3
5
6
8
14
16
38
55
55
55
61
64
64
72
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
4
3
2
3
4
4
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
-305.21
-64.85
-29.52
-67.48
-70.52
-40.16
-147.18
- -
Operating Margin (%)
- -
- -
- -
2
2
1
1
1
1
- -
- -
- -
- -
1
1
5
Depreciation Expense
-17
-14
-6
-5
-7
-13
-4
-2
-5
-1
-1
-1
-2
-2
-6
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
-660.17
-27.41
-27.44
-63.65
-68.09
-39.34
-152.34
- -
Profit Margin (%)
-5
-2
6
4
4
- -
1
-1
1
- -
1
- -
8
5
1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
14
17
6
11
10
7
6
4
8
5
5
5
20
18
14
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-51.09
-24.81
-10.06
-39.24
-93.01
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.65%
45.29%
-42.85%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
30.01%
76.73%
56.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4
2024
- -
- -
- -
- -
4
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.09
2025
- -
- -
- -
- -
-0.12

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
DongKook Pharmaceutical Co., Ltd. (086450.KQ)
Herborium Group, Inc. (HBRM)
Live Verdure Ltd (LV1.AX)
Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.NS)
Teva Pharmaceutical Industries Limited (TEVA)
Alivus Life Sciences Limited (ALIVUS.BO)
Business
Invion Limited (ASX:IVX) is a clinical-stage Australian life sciences company that researches and develops Photosoft technology, a next-generation photodynamic therapy (PDT) platform utilizing photosensitizing compounds, oxygen, and light to generate reactive oxygen species for selective destruction of cancer cells and stimulation of anti-cancer immune responses; the lead candidate INV043, an enhanced chlorin-based photosensitizer, targets non-melanoma skin cancers via topical application, solid tumors such as ovarian, prostate, lung, glioblastoma multiforme, triple-negative breast cancer, pancreatic, and ano-genital cancers via intravenous administration, and infectious diseases including periodontal conditions, wound healing, atherosclerosis, antibiotic-resistant bacteria like MRSA, fungi such as Candida albicans, and viruses like Zika, Dengue, and SARS-CoV-2; Photosoft demonstrates theragnostic potential for both treatment and imaging, synergizes with immune checkpoint inhibitors to enhance tumor control, and offers a minimally invasive alternative to surgery with reduced side effects. Founded in 2000 and headquartered in Melbourne, Australia, Invion operates primarily in oncology and infectious disease segments, serving global markets through exclusive perpetual licenses for cancer indications in Australia, New Zealand, and Asia Pacific (excluding China but including Hong Kong, Macau, Taiwan, Japan, South Korea), plus rights for atherosclerosis and infectious diseases extending to North America including the United States and Canada. Recent developments include a September 2023 expansion of Photosoft cancer rights to South Korea, supported by A$0.9 million contribution to prior costs and shared sub-licensing economics with licensor RMW Cho Group; a July 2023 grant of an Australian patent extending IP protection for INV043 to 2041; ongoing preclinical collaborations with Hudson Institute of Medical Research and Peter MacCallum Cancer Centre yielding proof-of-concept data for tumor regression and ICI combinations; funded partnerships with South Korean firms Hanlim Pharm for glioblastoma and oesophageal cancer, and Dr. I&B for HPV-related indications; a October 2025 funded collaboration agreement with Protect Animal Health; advancement toward Phase I adaptive platform trials for non-melanoma skin and ano-genital cancers in 2024-2025, with additional Phase I studies planned for intravenous solid tumors and oral microbial diseases; and quarterly activities confirming progress as of September 2025.